CD44v6 expression in non-anaplastic thyroid carcinoma: characterization of candidates for targeted therapy
Substantial subsets of non-ATCs express CD44v6, indicating that some patients may be candidates for [<sup>1</sup>⁷⁷Lu]Lu-DOTA-AKIR001 radiotherapy, particularly when conventional treatments are exhausted.
Authors
- Jan Zedenius (ORCID: https://orcid.org/0000-0003-2833-3758)
- Adam Stenman (ORCID: https://orcid.org/0000-0003-3248-7629)
- Vincenzo Condello (ORCID: https://orcid.org/0000-0003-4569-5398)
- Marika Nestor (ORCID: https://orcid.org/0000-0003-4662-3142)
- C. Christofer Juhlin (ORCID: https://orcid.org/0000-0002-5945-9081)
- Anja C. Mortensen (ORCID: https://orcid.org/0000-0002-6771-3289)
- Joachim N. Nilsson (ORCID: https://orcid.org/0000-0001-7496-9189)
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Science for Life Laboratory (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Thyroid Research
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1186/s13044-025-00266-3
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sjöbergstiftelsen
- Cancerfonden
- Karolinska Institutet
- Vetenskapsrådet